Artiene Tatian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Artiene Tatian has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Orli Wargon
Department of Dermatology Sydney Children's Hospital Randwick New South Wales Australia
3 shared publications - Geoffrey D. Cains
University of New South Wales Sydney New South Wales Australia
2 shared publications - Joseph Joseph
Department of Dermatology Sydney Children's Hospital Randwick New South Wales Australia
2 shared publications - Kelvin Truong
Department of Dermatology Sydney Children's Hospital Randwick New South Wales Australia
2 shared publications - Samuel Der Sarkissian
Concord Repatriation General Hospital New South Wales Australia
2 shared publications - Alexandra Murray
Department of Dermatology Westmead Hospital Westmead New South Wales Australia
1 shared publication
Latest Publications
- Open Access
- 3 November 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (11)
Development of a rapid LAMP assay toward point-of-care detection of dermatophyte infections and antifungal resistance
Dermatophytosis is a common fungal infection affecting up to 25% of the global population. Increasing antifungal resistance and limited access to timely diagnostics hamper effective management, particularly in resource-limited settings. There is therefore an urgent need for reliable point-of-care diagnostics to guide treatment and support antifungal stewardship. Here, we report the development and validation of molecular assays based on loop-mediated isothermal amplification (LAMP) for rapid identification of dermatophytes and antifungal resistance-associated alleles. For taxonomic identification, we developed conventional LAMP assays targeting pan-dermatophytes, Microsporum spp., Trichophyton rubrum complex, and Trichophyton mentagrophytes complex. For detection of single-nucleotide polymorphisms (SNPs) associated with terbinafine resistance, we developed competitive SNP-based LAMP (sbLAMP) assays using unmodified self-stabilizing (USS) primers to differentiate specific from non-specific amplification. At 65°C, pan-dermatophyte, Microsporum spp., T. rubrum complex, and T. mentagrophytes complex samples were detected in less than 9 min of assay start, with Microsporum detection possible in less than 6 min. Limits of detection were 10 gene copies per reaction for T. mentagrophytes and 100–1,000 gene copies per reaction for the remaining assays. Using available clinical isolates, assays demonstrated sensitive and specific detection and were compatible with a simple colorimetric readout. For resistance detection, optimized primers validated wild-type allelic status of T. rubrum isolates, showing delayed amplification in mutant assays. Together, these assays show a means by which taxonomic identification and allele-specific resistance detection of dermatophyte infections might be possible within a point-of-care application. Such an application could support targeted treatment in remote or resource-limited settings that will also aid in the stewardship of emerging antifungal resistance. IMPORTANCE: Antifungal resistance is an emerging global health threat, with the World Health Organization identifying inadequate fungal diagnostics as a major barrier to effective treatment and surveillance. Dermatophyte infections affect up to one-quarter of the global population, yet diagnosis remains slow, laboratory-dependent, and often inaccessible in the communities most affected. This diagnostic gap contributes to empirical antifungal use, delayed treatment, and the emergence of resistance to frontline therapies, such as terbinafine. Here, we present a proof-of-concept molecular diagnostic platform based on loop-mediated isothermal amplification (LAMP) for the rapid identification of dermatophyte infections and associated antifungal resistance markers. By integrating species-level detection with allele-specific resistance profiling in a rapid, low-cost, and portable format, these assays provide a foundation for future point-of-care diagnostics that could improve access to timely fungal diagnosis, enable targeted antifungal therapy, and strengthen global antifungal stewardship, particularly in resource-limited settings.
- 3 November 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (11)
Open AccessDevelopment of a rapid LAMP assay toward point-of-care detection of dermatophyte infections and antifungal resistance
Dermatophytosis is a common fungal infection affecting up to 25% of the global population. Increasing antifungal resistance and limited access to timely diagnostics hamper effective management, particularly in resource-limited settings. There is therefore an urgent need for reliable point-of-care diagnostics to guide treatment and support antifungal stewardship. Here, we report the development and validation of molecular assays based on loop-mediated isothermal amplification (LAMP) for rapid identification of dermatophytes and antifungal resistance-associated alleles. For taxonomic identification, we developed conventional LAMP assays targeting pan-dermatophytes, Microsporum spp., Trichophyton rubrum complex, and Trichophyton mentagrophytes complex. For detection of single-nucleotide polymorphisms (SNPs) associated with terbinafine resistance, we developed competitive SNP-based LAMP (sbLAMP) assays using unmodified self-stabilizing (USS) primers to differentiate specific from non-specific amplification. At 65°C, pan-dermatophyte, Microsporum spp., T. rubrum complex, and T. mentagrophytes complex samples were detected in less than 9 min of assay start, with Microsporum detection possible in less than 6 min. Limits of detection were 10 gene copies per reaction for T. mentagrophytes and 100–1,000 gene copies per reaction for the remaining assays. Using available clinical isolates, assays demonstrated sensitive and specific detection and were compatible with a simple colorimetric readout. For resistance detection, optimized primers validated wild-type allelic status of T. rubrum isolates, showing delayed amplification in mutant assays. Together, these assays show a means by which taxonomic identification and allele-specific resistance detection of dermatophyte infections might be possible within a point-of-care application. Such an application could support targeted treatment in remote or resource-limited settings that will also aid in the stewardship of emerging antifungal resistance. IMPORTANCE: Antifungal resistance is an emerging global health threat, with the World Health Organization identifying inadequate fungal diagnostics as a major barrier to effective treatment and surveillance. Dermatophyte infections affect up to one-quarter of the global population, yet diagnosis remains slow, laboratory-dependent, and often inaccessible in the communities most affected. This diagnostic gap contributes to empirical antifungal use, delayed treatment, and the emergence of resistance to frontline therapies, such as terbinafine. Here, we present a proof-of-concept molecular diagnostic platform based on loop-mediated isothermal amplification (LAMP) for the rapid identification of dermatophyte infections and associated antifungal resistance markers. By integrating species-level detection with allele-specific resistance profiling in a rapid, low-cost, and portable format, these assays provide a foundation for future point-of-care diagnostics that could improve access to timely fungal diagnosis, enable targeted antifungal therapy, and strengthen global antifungal stewardship, particularly in resource-limited settings.
- Open Access
- 17 October 2026
- Published by Wiley in Australasian Journal of Dermatology
Real‐World Outcomes of Rituximab in Pemphigus: An Australian Tertiary Cohort
Rituximab is endorsed internationally as first‐line therapy for moderate‐to‐severe pemphigus, but Australian guidelines position it as a rescue agent and local outcome data are limited. In this single‐centre retrospective cohort, 24 adults with pemphigus vulgaris ( n = 16) or pemphigus foliaceus ( n = 8) received rituximab as part of routine care; median follow‐up from first infusion was 24.9 months. Disease control was documented in all patients and complete remission in 20 (83%), of whom half subsequently relapsed despite most receiving more than one cycle. Adverse events occurred in eight patients (33%), predominantly mild infusion‐related reactions, with one fatal pneumonia. These real‐world data support planned maintenance after remission rather than single‐course rescue use, and prospective multicentre study with standardised severity scoring.
- 17 October 2026
- Published by Wiley in Australasian Journal of Dermatology
Open AccessReal‐World Outcomes of Rituximab in Pemphigus: An Australian Tertiary Cohort
Rituximab is endorsed internationally as first‐line therapy for moderate‐to‐severe pemphigus, but Australian guidelines position it as a rescue agent and local outcome data are limited. In this single‐centre retrospective cohort, 24 adults with pemphigus vulgaris ( n = 16) or pemphigus foliaceus ( n = 8) received rituximab as part of routine care; median follow‐up from first infusion was 24.9 months. Disease control was documented in all patients and complete remission in 20 (83%), of whom half subsequently relapsed despite most receiving more than one cycle. Adverse events occurred in eight patients (33%), predominantly mild infusion‐related reactions, with one fatal pneumonia. These real‐world data support planned maintenance after remission rather than single‐course rescue use, and prospective multicentre study with standardised severity scoring.
- Open Access
- 26 July 2026
- Published by Wiley in Australasian Journal of Dermatology
A Systematic Review of Topical and Systemic Gentamicin for Wound Healing in Patients With Junctional and Dystrophic Epidermolysis Bullosa
Epidermolysis bullosa (EB) is an inherited mechanobullous genodermatosis caused by a mutation in genes encoding proteins integral to skin integrity. Premature termination codon readthrough therapies, such as gentamicin, have promise in facilitating full‐length protein expression in patients with EB. We conducted a systematic review of the effectiveness and adverse effects of gentamicin for wound healing in EB. Six databases were searched to 01 September 2025 for clinical trials investigating gentamicin for EB. Risk of bias was assessed using the ROBINS‐I tool, and data were synthesised descriptively. This study was registered with PROSPERO (CRD42024496582). Five studies involving 24 patients with junctional EB or dystrophic EB were included; four were open‐label and one was double‐blinded. Nineteen of the 24 patients had a known nonsense mutation. Gentamicin was administered topically (two studies), intravenously (two studies) and both topically and intradermally (one study). Wound healing was heterogeneously measured across studies, with all but one showing improved outcomes. All patients demonstrated increased expression of glycoprotein or collagen in skin biopsy specimens after gentamicin treatment. No adverse events were noted. However, four of five studies were at serious risk of bias on ROBINS‐I, primarily owing to lack of blinding and absence of control groups, increasing the risk of bias for subjective outcomes such as wound healing. The available evidence suggests gentamicin may improve wound healing in EB caused by nonsense mutations, but the small number of heterogeneous studies precludes high‐level evidence. Larger, blinded, randomised trials are required to confirm efficacy and long‐term safety.
- 26 July 2026
- Published by Wiley in Australasian Journal of Dermatology
Open AccessA Systematic Review of Topical and Systemic Gentamicin for Wound Healing in Patients With Junctional and Dystrophic Epidermolysis Bullosa
Epidermolysis bullosa (EB) is an inherited mechanobullous genodermatosis caused by a mutation in genes encoding proteins integral to skin integrity. Premature termination codon readthrough therapies, such as gentamicin, have promise in facilitating full‐length protein expression in patients with EB. We conducted a systematic review of the effectiveness and adverse effects of gentamicin for wound healing in EB. Six databases were searched to 01 September 2025 for clinical trials investigating gentamicin for EB. Risk of bias was assessed using the ROBINS‐I tool, and data were synthesised descriptively. This study was registered with PROSPERO (CRD42024496582). Five studies involving 24 patients with junctional EB or dystrophic EB were included; four were open‐label and one was double‐blinded. Nineteen of the 24 patients had a known nonsense mutation. Gentamicin was administered topically (two studies), intravenously (two studies) and both topically and intradermally (one study). Wound healing was heterogeneously measured across studies, with all but one showing improved outcomes. All patients demonstrated increased expression of glycoprotein or collagen in skin biopsy specimens after gentamicin treatment. No adverse events were noted. However, four of five studies were at serious risk of bias on ROBINS‐I, primarily owing to lack of blinding and absence of control groups, increasing the risk of bias for subjective outcomes such as wound healing. The available evidence suggests gentamicin may improve wound healing in EB caused by nonsense mutations, but the small number of heterogeneous studies precludes high‐level evidence. Larger, blinded, randomised trials are required to confirm efficacy and long‐term safety.
- Open Access
- 5 June 2026
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 62 (8) , 1450-1457
Management of Kaposiform Haemangioendothelioma—A Retrospective Case Series Examining the Use and Effectiveness of Vincristine
Aim: Kaposiform haemangioendothelioma is a rare vascular tumour. Management has evolved over the last two decades, with most cases receiving vincristine or sirolimus. We aim to describe our experience with managing this tumour, with a focus on the safety and efficacy of vincristine. Methods: A retrospective cohort study of all cases treated at Sydney Children's Hospital over a 19‐year period was conducted. Explanatory variables included age, tumour location, imaging, the presence of Kasabach‐Merrit Phenomenon, and treatment modality. The primary outcome was disease recurrence and the secondary outcome, complications. Results: Twenty‐one cases were identified with 13 (60%) presenting as neonates. The most common site was limb; and imaging included ultrasound (7/21, 33%) and MRI (12/21, 57%). Almost all had consumptive coagulopathy (20/21, 95%) with 6/21 (29%) having severe Kasabach‐Merrit Phenomenon. Six tumours were excised and 16 (76%) were treated with vincristine, with three (14%) progressing to treatment with sirolimus. There were no recurrences. Complications of vincristine therapy were common but mild in most cases, with only one proven blood stream infection and one requiring central line replacement. Conclusion: Vincristine remains a highly effective first‐line treatment for kaposiform haemangioendothelioma with an acceptable safety profile. Further well‐designed multicentre trials are needed to objectively compare its effectiveness and safety with sirolimus.
- 5 June 2026
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 62 (8) , 1450-1457
Open AccessManagement of Kaposiform Haemangioendothelioma—A Retrospective Case Series Examining the Use and Effectiveness of Vincristine
Aim: Kaposiform haemangioendothelioma is a rare vascular tumour. Management has evolved over the last two decades, with most cases receiving vincristine or sirolimus. We aim to describe our experience with managing this tumour, with a focus on the safety and efficacy of vincristine. Methods: A retrospective cohort study of all cases treated at Sydney Children's Hospital over a 19‐year period was conducted. Explanatory variables included age, tumour location, imaging, the presence of Kasabach‐Merrit Phenomenon, and treatment modality. The primary outcome was disease recurrence and the secondary outcome, complications. Results: Twenty‐one cases were identified with 13 (60%) presenting as neonates. The most common site was limb; and imaging included ultrasound (7/21, 33%) and MRI (12/21, 57%). Almost all had consumptive coagulopathy (20/21, 95%) with 6/21 (29%) having severe Kasabach‐Merrit Phenomenon. Six tumours were excised and 16 (76%) were treated with vincristine, with three (14%) progressing to treatment with sirolimus. There were no recurrences. Complications of vincristine therapy were common but mild in most cases, with only one proven blood stream infection and one requiring central line replacement. Conclusion: Vincristine remains a highly effective first‐line treatment for kaposiform haemangioendothelioma with an acceptable safety profile. Further well‐designed multicentre trials are needed to objectively compare its effectiveness and safety with sirolimus.
- Open Access
- 4 September 2025
- Published by Wiley in JEADV Clinical Practice
- Vol. 5 (1) , 153-162
The Efficacy and Safety of Atenolol for Treatment of Infantile Hemangioma
Background: Infantile hemangiomas are the most common benign vascular tumours in children. Since the discovery of propranolol for infantile hemangiomas, its increasing side effect profile has prompted research into its beta‐1‐selective counterpart, atenolol. Studies have shown that atenolol is equally effective and more tolerable than propranolol. However, there remains a lack of consensus surrounding atenolol standard dosing and escalation guidelines. Objectives: To retrospectively assess the efficacy and side effects of atenolol used for children with infantile hemangiomas requiring oral beta‐blocker therapy. Methods: A retrospective cohort study at a tertiary dermatology clinic from January 2022 to September 2023 identified infants treated with atenolol for infantile hemangiomas. Infant demographic, lesion characteristics and treatment outcomes were analysed and compared between those who received 1, 1.5 or 2 mg/kg/day of oral atenolol. Results: Of 83 eligible patients, 14.4% ( n = 12) remained on 1 mg/kg/day, 42.2% ( n = 35) received 1.5 mg/kg/day, and 43.4% ( n = 36) increased to 2 mg/kg/day. Overall, 98.8% ( n = 82) responded to atenolol, with 88% ( n = 73) exhibiting a substantial response. Complete involution was associated with earlier age of atenolol commencement ( p = 0.009). Lesions that required escalation to 2 mg/kg/day were more commonly associated with anatomical disfigurement ( p = 0.0121), or were deep, mixed, periorbital, lip or nose infantile hemangiomas. Lesions causing functional impairment were associated with a longer duration of treatment ( p < 0.001). Adverse effects requiring treatment cessation occurred in 3.6% ( n = 3), all being behavioural changes. Conclusions: Atenolol has proven to be an efficacious, safe and tolerable medication for infantile hemangiomas and is a suitable alternative to propanolol. Almost all infants responded to atenolol therapy with more than 50% responding adequately to 1.5 mg/kg/day or less. Infants may be safely commenced on these lower doses with grading up according to response, rather than routinely escalating to 2 mg/kg/day.
- 4 September 2025
- Published by Wiley in JEADV Clinical Practice
- Vol. 5 (1) , 153-162
Open AccessThe Efficacy and Safety of Atenolol for Treatment of Infantile Hemangioma
Background: Infantile hemangiomas are the most common benign vascular tumours in children. Since the discovery of propranolol for infantile hemangiomas, its increasing side effect profile has prompted research into its beta‐1‐selective counterpart, atenolol. Studies have shown that atenolol is equally effective and more tolerable than propranolol. However, there remains a lack of consensus surrounding atenolol standard dosing and escalation guidelines. Objectives: To retrospectively assess the efficacy and side effects of atenolol used for children with infantile hemangiomas requiring oral beta‐blocker therapy. Methods: A retrospective cohort study at a tertiary dermatology clinic from January 2022 to September 2023 identified infants treated with atenolol for infantile hemangiomas. Infant demographic, lesion characteristics and treatment outcomes were analysed and compared between those who received 1, 1.5 or 2 mg/kg/day of oral atenolol. Results: Of 83 eligible patients, 14.4% ( n = 12) remained on 1 mg/kg/day, 42.2% ( n = 35) received 1.5 mg/kg/day, and 43.4% ( n = 36) increased to 2 mg/kg/day. Overall, 98.8% ( n = 82) responded to atenolol, with 88% ( n = 73) exhibiting a substantial response. Complete involution was associated with earlier age of atenolol commencement ( p = 0.009). Lesions that required escalation to 2 mg/kg/day were more commonly associated with anatomical disfigurement ( p = 0.0121), or were deep, mixed, periorbital, lip or nose infantile hemangiomas. Lesions causing functional impairment were associated with a longer duration of treatment ( p < 0.001). Adverse effects requiring treatment cessation occurred in 3.6% ( n = 3), all being behavioural changes. Conclusions: Atenolol has proven to be an efficacious, safe and tolerable medication for infantile hemangiomas and is a suitable alternative to propanolol. Almost all infants responded to atenolol therapy with more than 50% responding adequately to 1.5 mg/kg/day or less. Infants may be safely commenced on these lower doses with grading up according to response, rather than routinely escalating to 2 mg/kg/day.
- 2 September 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (7)
Safety and Efficacy of Angiotensin Receptor Antagonists in Recessive Dystrophic Epidermolysis Bullosa
Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited progressive blistering skin disorder caused by mutations in the COL7A1 gene. Chronic wounds lead to cycles of scarring and healing, causing severe functional deformities. Losartan is an angiotensin II type 1 receptor (AT1R) antagonist that has been shown to have antifibrotic activity via inhibiting the production of transforming growth factor beta (TGF‐B) and has a favourable safety profile in children. In this systematic review, there were five studies found, with a total of 59 patients including case series, case–control and an open label phase 2 clinical trial. These studies have demonstrated the safety of losartan with no significant adverse effects such as hypotension, hyperkalaemia and hypersensitivity. They have also demonstrated evidence of efficacy utilising subjective assessments and objective criteria such as the Birmingham Epidermolysis Bullosa Severity score (BEBS) and Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). Although safe and effective, further clinical trials are required to fully elucidate the role of this treatment; whether this approach should be standardised across the RDEB patient cohort is yet to be determined from the current evidence. Trial Registration: PROSPERO ID: CRD42024557126
- 2 September 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (7)
Safety and Efficacy of Angiotensin Receptor Antagonists in Recessive Dystrophic Epidermolysis Bullosa
Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited progressive blistering skin disorder caused by mutations in the COL7A1 gene. Chronic wounds lead to cycles of scarring and healing, causing severe functional deformities. Losartan is an angiotensin II type 1 receptor (AT1R) antagonist that has been shown to have antifibrotic activity via inhibiting the production of transforming growth factor beta (TGF‐B) and has a favourable safety profile in children. In this systematic review, there were five studies found, with a total of 59 patients including case series, case–control and an open label phase 2 clinical trial. These studies have demonstrated the safety of losartan with no significant adverse effects such as hypotension, hyperkalaemia and hypersensitivity. They have also demonstrated evidence of efficacy utilising subjective assessments and objective criteria such as the Birmingham Epidermolysis Bullosa Severity score (BEBS) and Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). Although safe and effective, further clinical trials are required to fully elucidate the role of this treatment; whether this approach should be standardised across the RDEB patient cohort is yet to be determined from the current evidence. Trial Registration: PROSPERO ID: CRD42024557126
- Open Access
Safety and Efficacy of Pemphigus Treatments: A Subtype-Specific Review of Conventional and Emerging Therapies
Background/Objectives: Pemphigus is a rare blistering disease characterized by a chronic course, associated with significant mortality and morbidity. This review article aims to delve into three Pemphigus subtypes: Pemphigus Vulgaris, Pemphigus Foliaceus and Paraneoplastic Pemphigus, including the safety and efficacy of their treatment options. Methods: A thorough literature search was conducted using PubMed, EMBASE, Medline and Cochrane Library to collate data on pharmaceutical treatments of Pemphigus. Studies were selected based on predefined inclusion criteria, which included English language, peer-reviewed articles published in the date range January 2000 to May 2025. Eligible studies involved adults diagnosed with Pemphigus Vulgaris, Pemphigus Foliaceus or Paraneoplastic Pemphigus who were treated with Glucocorticoids, Mycophenolate mofetil, azathioprine or rituximab. The focus was on identifying adverse effects, complete remission and relapse rates. Results: The analysis revealed that glucocorticoid is the first-line treatment for Pemphigus. However, low remission rates of 34% along with steroid-related adverse effects indicate the use of Mycophenolate and azathioprine as steroid-sparing adjuvant therapies. Emerging treatments with rituximab have demonstrated 90% remission rates, indicating promising results with a comparatively mild side effect profile. Conclusions: The findings highlight the importance of ongoing evaluation of treatment modalities for Pemphigus subtypes to optimise remission rates and minimise adverse effects. Ultimately, studies often fail to isolate specific Pemphigus subtypes owing to the scarcity of literature. There is also a crucial need to address the lack of a standardised grading system for the side effects of glucocorticoids and long-term safety data for rituximab in further longitudinal research.
Open AccessSafety and Efficacy of Pemphigus Treatments: A Subtype-Specific Review of Conventional and Emerging Therapies
Background/Objectives: Pemphigus is a rare blistering disease characterized by a chronic course, associated with significant mortality and morbidity. This review article aims to delve into three Pemphigus subtypes: Pemphigus Vulgaris, Pemphigus Foliaceus and Paraneoplastic Pemphigus, including the safety and efficacy of their treatment options. Methods: A thorough literature search was conducted using PubMed, EMBASE, Medline and Cochrane Library to collate data on pharmaceutical treatments of Pemphigus. Studies were selected based on predefined inclusion criteria, which included English language, peer-reviewed articles published in the date range January 2000 to May 2025. Eligible studies involved adults diagnosed with Pemphigus Vulgaris, Pemphigus Foliaceus or Paraneoplastic Pemphigus who were treated with Glucocorticoids, Mycophenolate mofetil, azathioprine or rituximab. The focus was on identifying adverse effects, complete remission and relapse rates. Results: The analysis revealed that glucocorticoid is the first-line treatment for Pemphigus. However, low remission rates of 34% along with steroid-related adverse effects indicate the use of Mycophenolate and azathioprine as steroid-sparing adjuvant therapies. Emerging treatments with rituximab have demonstrated 90% remission rates, indicating promising results with a comparatively mild side effect profile. Conclusions: The findings highlight the importance of ongoing evaluation of treatment modalities for Pemphigus subtypes to optimise remission rates and minimise adverse effects. Ultimately, studies often fail to isolate specific Pemphigus subtypes owing to the scarcity of literature. There is also a crucial need to address the lack of a standardised grading system for the side effects of glucocorticoids and long-term safety data for rituximab in further longitudinal research.
- Open Access
- 31 July 2023
- Published by Wiley in JEADV Clinical Practice
- Vol. 2 (4) , 968-969
Perianal non‐septicaemic ecthyma gangrenosum caused by Klebsiella pneumoniae
- 31 July 2023
- Published by Wiley in JEADV Clinical Practice
- Vol. 2 (4) , 968-969
Open AccessPerianal non‐septicaemic ecthyma gangrenosum caused by Klebsiella pneumoniae
- Open Access
- 31 December 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 188 (5) , 673-675
The association between pilonidal sinus disease and hidradenitis suppurativa: a systematic review and meta-analysis
We performed a systematic review and meta-analysis examining the association between hidradenitis suppurativa (HS) and pilonidal sinus disease (PSD). We found a strong association between HS and PSD, with an increased occurrence of PSD in individuals with HS compared with unaffected controls. Given this strong association, patients with HS should be assessed for PSD.
- 31 December 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 188 (5) , 673-675
Open AccessThe association between pilonidal sinus disease and hidradenitis suppurativa: a systematic review and meta-analysis
We performed a systematic review and meta-analysis examining the association between hidradenitis suppurativa (HS) and pilonidal sinus disease (PSD). We found a strong association between HS and PSD, with an increased occurrence of PSD in individuals with HS compared with unaffected controls. Given this strong association, patients with HS should be assessed for PSD.
- Open Access
- 30 August 2022
- Published by Wiley in Experimental Dermatology
- Vol. 31 (12) , 1872-1880
Adalimumab therapy is associated with increased faecal short chain fatty acids in hidradenitis suppurativa
Altered gut microbiota composition has been observed in individuals with hidradenitis suppurutiva (HS) and many other inflammatory diseases, including obesity, type 1 and type 2 diabetes. Here, we addressed whether adalimumab, a systemic anti‐inflammatory therapy, may impact the microbiota biochemical profile, particularly on beneficial metabolites such as short‐chain fatty acids (SCFAs). We conducted an observational single‐arm pilot trial to assess gut microbiota composition by 16S rRNA gene sequence analysis and to detect metabolite signatures by gas chromatography in stool samples from participants with HS prior to and 12 weeks after commencing adalimumab therapy. HS individuals that better responded to adalimumab treatment showed a shift in the composition and function of the gut microbiota with significantly increased SCFA acetate and propionate compared to age, gender and BMI‐matched healthy controls. A positive correlation was observed between propionate with Prevotella sp and Faecalibacterium prausnitsii. Increased SCFAs, changes in gut microbiota composition, function and metabolic profile following 12 weeks of adalimumab suggest that targeting SCFAs may be considered a potential biomarker to be evaluated as a complementary protective factor or as a diagnostically relevant signal in HS.
- 30 August 2022
- Published by Wiley in Experimental Dermatology
- Vol. 31 (12) , 1872-1880
Open AccessAdalimumab therapy is associated with increased faecal short chain fatty acids in hidradenitis suppurativa
Altered gut microbiota composition has been observed in individuals with hidradenitis suppurutiva (HS) and many other inflammatory diseases, including obesity, type 1 and type 2 diabetes. Here, we addressed whether adalimumab, a systemic anti‐inflammatory therapy, may impact the microbiota biochemical profile, particularly on beneficial metabolites such as short‐chain fatty acids (SCFAs). We conducted an observational single‐arm pilot trial to assess gut microbiota composition by 16S rRNA gene sequence analysis and to detect metabolite signatures by gas chromatography in stool samples from participants with HS prior to and 12 weeks after commencing adalimumab therapy. HS individuals that better responded to adalimumab treatment showed a shift in the composition and function of the gut microbiota with significantly increased SCFA acetate and propionate compared to age, gender and BMI‐matched healthy controls. A positive correlation was observed between propionate with Prevotella sp and Faecalibacterium prausnitsii. Increased SCFAs, changes in gut microbiota composition, function and metabolic profile following 12 weeks of adalimumab suggest that targeting SCFAs may be considered a potential biomarker to be evaluated as a complementary protective factor or as a diagnostically relevant signal in HS.